Literature DB >> 10874282

Esmolol versus diltiazem in the treatment of postoperative atrial fibrillation/atrial flutter after open heart surgery.

A N Mooss1, R L Wurdeman, S M Mohiuddin, A P Reyes, J T Sugimoto, W Scott, D E Hilleman, A Seyedroudbari.   

Abstract

BACKGROUND: Supraventricular tachyarrhythmias are common after open heart surgery. Possible causative factors for these arrhythmias include operative trauma, atrial ischemia, electrolyte imbalances, pericardial irritation, and excess catecholamines. Two agents commonly used to control ventricular rate in atrial fibrillation or atrial flutter (AF/AFL) are beta-blockers and calcium channel blockers. METHODS AND
RESULTS: This randomized study was designed to compare the safety and efficacy of intravenous diltiazem versus intravenous esmolol in patients with postoperative AF/AFL after coronary bypass surgery and/or valve replacement surgery. A comparative cost analysis was also performed. Thirty patients received either esmolol (n = 15) or diltiazem (n = 15) for AF/AFL. During the first 6 hours of treatment, 66.6% of esmolol-treated patients converted to sinus rhythm compared with 13.3% of the diltiazem-treated patients (P <.05). At 24 hours, 66.6% of the diltiazem group converted to SR compared with 80% of the esmolol group (not significant). Drug-induced side effects, time to rate control (<90 beats/min), number of patients requiring cardioversion, and length of hospitalization were similar for the two groups. The drug cost/successfully treated patient for esmolol versus diltiazem was $254 versus $437 at 6 hours and $529 versus $262 at 24 hours.
CONCLUSIONS: Although this is a small study, it suggests that esmolol is more effective in converting patients to normal sinus rhythm than diltiazem during the initial dosing period. No differences in conversion rates were observed between the two groups after 24 hours. Additional studies are needed to confirm whether esmolol is the initial drug of choice in patients with postoperative AF/AFL after coronary bypass surgery.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10874282     DOI: 10.1067/mhj.2000.106917

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  15 in total

1.  Efficacy of landiolol hydrochloride for atrial fibrillation after open heart surgery.

Authors:  Hiroyuki Nishi; Taichi Sakaguchi; Shigeru Miyagawa; Yasushi Yoshikawa; Satsuki Fukushima; Shunsuke Saito; Takayoshi Ueno; Toru Kuratani; Yoshiki Sawa
Journal:  Heart Vessels       Date:  2012-06-03       Impact factor: 2.037

2.  Practice Patterns and Outcomes of Treatments for Atrial Fibrillation During Sepsis: A Propensity-Matched Cohort Study.

Authors:  Allan J Walkey; Stephen R Evans; Michael R Winter; Emelia J Benjamin
Journal:  Chest       Date:  2016-01-06       Impact factor: 9.410

Review 3.  A review and analysis of strategies for prediction, prevention and management of post-operative atrial fibrillation after non-cardiac thoracic surgery.

Authors:  Heather Smith; Ching Yeung; Stephen Gowing; Mouhannad Sadek; Donna Maziak; Sebastien Gilbert; Farid Shamji; Patrick Villeneuve; Sudhir Sundaresan; Andrew Seely
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

4.  Use of landiolol in the perioperative management of supraventricular tachycardia.

Authors:  Hiroaki Ito; Kazuya Sobue; Minhye So; Hiroyuki Hirate; Takeshi Sugiura; Takafumi Azami; Hiroshi Sasano; Hirotada Katsuya
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

Review 5.  Rhythm control and cardioversion.

Authors:  N Sulke; F Sayers; G Y H Lip
Journal:  Heart       Date:  2006-09-08       Impact factor: 5.994

6.  Management of postoperative atrial fibrillation and subsequent outcomes in contemporary patients undergoing cardiac surgery: insights from the Society of Thoracic Surgeons CAPS-Care Atrial Fibrillation Registry.

Authors:  Benjamin A Steinberg; Yue Zhao; Xia He; Adrian F Hernandez; David A Fullerton; Kevin L Thomas; Roger Mills; Winslow Klaskala; Eric D Peterson; Jonathan P Piccini
Journal:  Clin Cardiol       Date:  2013-12-18       Impact factor: 2.882

Review 7.  Efficacy and safety of landiolol for prevention of atrial fibrillation after cardiac surgery: a meta-analysis of randomized controlled trials.

Authors:  Liang Li; Qing Ai; Ling Lin; Pu Ge; Changming Yang; Li Zhang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

8.  Management of Atrial Fibrillation with Rapid Ventricular Response in the Intensive Care Unit: A Secondary Analysis of Electronic Health Record Data.

Authors:  Ari Moskowitz; Kenneth P Chen; Avraham Z Cooper; Abdullah Chahin; Mohammad M Ghassemi; Leo Anthony Celi
Journal:  Shock       Date:  2017-10       Impact factor: 3.454

9.  The effectiveness and safety of landiolol hydrochloride, an ultra-short-acting β1-blocker, in postoperative patients with supraventricular tachyarrhythmias: a multicenter, randomized, double-blind, placebo-controlled study.

Authors:  Nobuyuki Taenaka; Shinichi Kikawa
Journal:  Am J Cardiovasc Drugs       Date:  2013-10       Impact factor: 3.571

10.  Dose-dependent effect of landiolol, a new ultra-short-acting β(1)-blocker, on supraventricular tachyarrhythmias in postoperative patients.

Authors:  Nobuyuki Taenaka; Shinichi Kikawa
Journal:  Clin Drug Investig       Date:  2013-07       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.